News Releases

News Releases

Date Title
Feb 16, 2021 Sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for Vicineum™
FDA stated it is not currently planning to hold an advisory committee meeting Potential for Vicineum to be a best-in-class treatment with projected peak revenue of $1B-$3B globally, $400M-$900M in the US Company to hold conference call at 8am ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb.
Feb 12, 2021 Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide a Business Update
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 12, 2021-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Dr. Thomas Cannell , President and CEO will host a conference call on Tuesday,
Feb 1, 2021 Sesen Bio Announces Successful Application Orientation Meeting (AOM) with the FDA for Vicineum™
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 1, 2021-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that on January 29, 2021 the Company participated in a productive Application
Jan 13, 2021 Sesen Bio and Qilu Pharmaceutical Announce IND Application for Vicineum™ Accepted for Review by the National Medical Products Administration in China
Clinical trial expected to be initiated shortly after NMPA approval of the IND Sesen Bio to receive $3M milestone payment upon IND approval CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 13, 2021-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for
Displaying 11 - 14 of 14

© 2021 Sesen Bio. All Rights Reserved.

Top